{"prompt": "['Product: MK-3475', '99', 'Protocol/Amendment No.: 604-09', 'Relationship', 'The following components are to be used to assess the relationship between the test drug and the AE: (continued)', \"to Sponsor's\", 'Dechallenge', \"Was the Sponsor's product discontinued or dose/exposure/frequency reduced?\", 'Product', 'If yes, did the AE resolve or improve?', '(continued)', 'If yes, this is a positive dechallenge. If no, this is a negative dechallenge.', '(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent disability; (2) the AE resolved/improved despite continuation', 'of', \"the Sponsor's product; or (3) the trial is a single-dose drug trial); or (4) Sponsor's product(s) is/are only used one time.)\", 'Rechallenge', \"Was the subject re-exposed to the Sponsor's product in this study?\", 'If yes, did the AE recur or worsen?', 'If yes, this is a positive rechallenge. If no, this is a negative rechallenge.', '(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent disability, or (2) the trial is a single-dose drug trial); or', \"(3) Sponsor's product(s) is/are used only one time).\", 'NOTE: IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH WAS SERIOUS AND WHICH MAY HAVE BEEN', \"CAUSED BY THE SPONSOR'S PRODUCT, OR IF REEXPOSURE TO THE SPONSOR'S PRODUCT POSES ADDITIONAL POTENTIAL\", 'SIGNIFICANT RISK TO THE SUBJECT, THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY THE SPONSOR', 'CLINICAL DIRECTOR AS PER DOSE MODIFICATION GUIDELINES IN THE PROTOCOL.', 'Consistency', \"Is the clinical/pathological presentation of the AE consistent with previous knowledge regarding the Sponsor's product or drug class pharmacology\", 'with', 'Trial', 'or toxicology?', 'Treatment', 'Profile', 'The assessment of relationship will be reported on the case report forms /worksheets by an investigator who is a qualified physician according to his/her best clinical judgment, including', 'consideration of the above elements.', 'Record one of the following', \"Use the following scale of criteria as guidance (not all criteria must be present to be indicative of a Sponsor's product relationship).\", 'Yes, there is a reasonable', \"There is evidence of exposure to the Sponsor's product. The temporal sequence of the AE onset relative to the administration of the Sponsor's\", \"possibility of Sponsor's product\", \"product is reasonable. The AE is more likely explained by the Sponsor's product than by another cause.\", 'relationship.', \"No, there is not a reasonable Subject did not receive the Sponsor's product OR temporal sequence of the AE onset relative to administration of the Sponsor's product is not\", \"possibility of Sponsor's product reasonable OR the AE is more likely explained by another cause than the Sponsor's product. (Also entered for a subject with overdose without an\", 'relationship', 'associated AE.)', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '100', 'Protocol/Amendment No.: 604-09', '7.2.5 Sponsor Responsibility for Reporting Adverse Events', 'All Adverse Events will be reported to regulatory authorities, IRB/IECs and investigators in', 'accordance with all applicable global laws and regulations, i.e., per ICH Topic E6 (R1)', 'Guidelines for Good Clinical Practice.', '7.3 TRIAL GOVERNANCE AND OVERSIGHT', 'Executive Oversight Committee', 'The Executive Oversight Committee (EOC) comprises members of Sponsor Senior', 'Management. The EOC will receive and decide upon any recommendations made by the', 'DMC regarding the trial.', '7.3.1 Data Monitoring Committee', 'To supplement the routine trial monitoring outlined in this protocol, an external Data', 'Monitoring Committee (DMC) will monitor the interim data from this trial. The voting', 'members of the committee are external to the Sponsor. The members of the DMC must not', 'be involved with the trial in any other way (e.g., they cannot be trial investigators) and must', 'have no competing interests that could affect their roles with respect to the trial.', 'The DMC will make recommendations to the EOC regarding steps to ensure both subject', 'safety and the continued ethical integrity of the trial. Also, the DMC will review interim trial', 'results, consider the overall risk and benefit to trial participants (see Section 8.7 - Interim', 'Analyses) and recommend to the EOC if the trial should continue in accordance with the', 'protocol.', 'Specific details regarding composition, responsibilities, and governance, including the roles', 'and responsibilities of the various members and the Sponsor protocol team; meeting', 'facilitation; the trial governance structure; and requirements for and proper documentation of', 'DMC reports, minutes, and recommendations will be described in the DMC charter that is', 'reviewed and approved by all the DMC members.', 'A DMC recommendation will be communicated to the Sponsor as agreed in the DMC', 'Charter.', '8.0 STATISTICAL ANALYSIS PLAN', 'This section outlines the statistical analysis strategy and procedures for the study. If, after the', 'study has begun, changes are made to primary and/or key secondary hypotheses, or the', 'statistical methods related to those hypotheses, then the protocol will be amended (consistent', 'with ICH Guideline E9). Changes to exploratory or other non-confirmatory analyses made', 'after the protocol has been finalized, but prior to the conduct of any analysis, will be', 'documented in a supplemental statistical analysis plan (sSAP) and referenced in the Clinical', 'Study Report (CSR) for the study. The PRO analysis plan will also be included in the sSAP.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}